



University of Dundee

The Neuronal Actions of Leptin and the Implications for Treating Alzheimer's Disease

Hamilton, Kirsty; Harvey, Jenni

Published in:
Pharmaceuticals

DOI:
[10.3390/ph14010052](https://doi.org/10.3390/ph14010052)

Publication date:
2021

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
Hamilton, K., & Harvey, J. (2021). The Neuronal Actions of Leptin and the Implications for Treating Alzheimer's Disease. *Pharmaceuticals*, 14(1), 1-14. [52]. <https://doi.org/10.3390/ph14010052>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Review

The Neuronal Actions of Leptin and the Implications for Treating Alzheimer's Disease

Kirsty Hamilton and Jenni Harvey *

Systems Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK; k.u.hamilton@dundee.ac.uk

* Correspondence: j.z.harvey@dundee.ac.uk; Tel.: +44-1382-383359

Abstract: It is widely accepted that the endocrine hormone leptin controls food intake and energy homeostasis via activation of leptin receptors expressed on hypothalamic arcuate neurons. The hippocampal formation also displays raised levels of leptin receptor expression and accumulating evidence indicates that leptin has a significant impact on hippocampal synaptic function. Thus, cellular and behavioural studies support a cognitive enhancing role for leptin as excitatory synaptic transmission, synaptic plasticity and glutamate receptor trafficking at hippocampal Schaffer collateral (SC)-CA1 synapses are regulated by leptin, and treatment with leptin enhances performance in hippocampus-dependent memory tasks. Recent studies indicate that hippocampal temporoammonic (TA)-CA1 synapses are also a key target for leptin. The ability of leptin to regulate TA-CA1 synapses has important functional consequences as TA-CA1 synapses are implicated in spatial and episodic memory processes. Moreover, degeneration is initiated in the TA pathway at very early stages of Alzheimer's disease, and recent clinical evidence has revealed links between plasma leptin levels and the incidence of Alzheimer's disease (AD). Additionally, accumulating evidence indicates that leptin has neuroprotective actions in various AD models, whereas dysfunctions in the leptin system accelerate AD pathogenesis. Here, we review the data implicating the leptin system as a potential novel target for AD, and the evidence that boosting the hippocampal actions of leptin may be beneficial.



Citation: Hamilton, K.; Harvey, J. The Neuronal Actions of Leptin and the Implications for Treating Alzheimer's Disease. *Pharmaceuticals* **2021**, *14*, 52. <https://doi.org/10.3390/ph14010052>

Received: 17 December 2020

Accepted: 7 January 2021

Published: 11 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Keywords: Leptin; hippocampus; synaptic plasticity; tau; AMPA; Alzheimer's; amyloid; memory; synaptic transmission

1. Introduction

It is over 50 years since Hervey performed ground-breaking parabiosis experiments which suggested that a circulatory factor regulates food intake and body weight [1]. This factor has since been identified as the 16 kDa *ob* gene product, leptin, which is derived from the Greek word leptos, meaning thin [2]. The major site for the production of leptin is white adipose tissue, although leptin is also made in various other peripheral tissues, including skeletal muscle, placenta and mammary epithelium. The circulating plasma levels of leptin directly correlate to overall body fat content [3]. Although leptin is predominantly produced by peripheral tissues, it readily gains entry to the brain via a saturable transport process at the blood–brain barrier or via the cerebrospinal fluid [4]. Within the CNS, specific hypothalamic nuclei such as the arcuate nucleus and ventromedial hypothalamus are key targets for leptin. After a meal, circulating leptin levels increase, leading to a rise in the CNS levels of leptin which in turn signals a feeling of fullness. In contrast, after periods of starvation or fasting, the circulating leptin levels fall, which acts as a stimulus for feeding [5].

Studies in this area have been aided by the availability of rodents with naturally occurring mutations in the leptin and *lepR* genes. Mutations in the *ob* gene have been shown to underlie early-onset obesity, hypothermia, and hyperphagia in mice. Thus,

in *ob/ob* mice, there is a lack of leptin as a truncated leptin protein is generated that is unable to be secreted. In a different leptin-deficient mouse strain (*ob^{2J}/ob^{2J}*), a transposon is integrated into the *ob* gene, thereby preventing *ob* mRNA synthesis. Interestingly, *ob* gene mutations rarely occur in humans. However, cases of morbid obesity identified in families from Pakistan and Turkey have been linked to specific mutations in the *ob* gene. The low incidence of leptin-specific mutations in humans indicates that genetic abnormalities in the leptin system are not the principal route for the development of obesity in humans.

2. Leptin Receptors

2.1. Leptin Receptor Isoforms

Leptin produces its biological effects via activating the leptin receptor (LepR). Tartaglia and colleagues first isolated LepR from the choroid plexus, and six isoforms of the receptor have been identified (LepRa-f) [6]. The isoforms differ with respect to their C-terminal domain length, which in turn influences the signalling capacity of the different LepR isoforms. It is widely accepted that the long-form (LepRb) is the predominant signalling competent isoform due to the extended length of its C-terminal domain. Conversely, the short isoforms (LepRa,c,d,f) have shorter C-terminal domains and limited signalling capacity. LepRe is distinct as it lacks a transmembrane domain but it is thought to be a route for transporting leptin in the plasma, as it still retains leptin-binding capacity.

2.2. Leptin Receptor-Driven Signalling

LepRs are members of the class I cytokine receptor superfamily which signal via association with janus tyrosine kinases (JAKs) [7]. Leptin binding to its receptor promotes phosphorylation and subsequent activation of JAK2, leading to recruitment and stimulation of various downstream pathways including phosphoinositide 3-kinase (PI3K), ERK, and signal transducers and activators of transcription (STAT3). LepR signalling can be terminated via activation of SOCS1-3 (suppressor of cytokine signalling), which bind to phosphorylated JAK2, thereby limiting LepR-driven signalling [8]. In hippocampal neurons, activation of PI3K, ERK and STAT3 are implicated in LepR-driven regulation of synaptic function (Figure 1) [9].




Figure 1. Leptin receptor-driven signalling in neurons. The key signalling pathways activated following leptin binding to leptin receptors (LepRs) and subsequent activation of janus tyrosine kinase (JAK)2 are shown including signal transducers and activators of transcription (STAT3), Ras-Raf-MEK-MAPK and phosphoinositide 3-kinase (PI3K), which ultimately lead to gene transcriptional changes or altered ion channel function. LepR signalling is terminated following the production of suppressor of cytokine signalling (SOCS)3.

In rodents, LepR gene mutations result in leptin-insensitivity, which ultimately leads to development of early-onset obesity as well as several endocrine-related impairments [2]. In *db/db* mice, a truncated form of LepR is produced which is unable to signal via the conventional JAK-STAT signalling pathway. Conversely, in *fa/fa* rats, a single point mutation occurs that renders all the LepR isoforms signalling incompetent [2]. In a manner similar to the *ob* gene mutations, the incidence of human LepR gene mutations is also extremely low.

2.3. Leptin Receptor Expression in the CNS

In accordance with leptin's pivotal role in controlling energy homeostasis, LepRs are highly expressed in specific regions of the hypothalamus that govern food intake and body weight, such as arcuate nucleus and ventromedial hypothalamus [10,11]. Additionally, high levels of LepR expression are observed in many other brain regions, including the hippocampus and cortex [12,13]. This pattern of LepR expression in the CNS suggests potential important roles for leptin in higher brain functions. Indeed, early studies involving leptin-deficient (*ob/ob*) mice demonstrated that absence of leptin resulted in neurodevelopmental abnormalities, with specific impairments detected in hippocampal and cortical brain regions [14]. These deficits were readily reversed by leptin replacement, suggesting a role for leptin in neuronal development. In support of this hypothesis, a surge in leptin is observed during the critical period of postnatal development [15]. Subsequent studies in this area have identified that this postnatal leptin surge plays a critical role in development of key hypothalamic synaptic connections involved in control of energy homeostasis [16]. However, increasing evidence indicates that the modulatory effects of leptin are not restricted to early postnatal stages of development, as leptin is reported to markedly influence the functioning of the hippocampus in adulthood and during ageing. Thus, in adult, tissue treatment with leptin has a major impact on the cellular processes underlying hippocampal learning and memory, which has led to the proposal that this hormone acts as a potential cognitive enhancer [17,18]. In support of this possibility, deficits in hippocampus-specific processes, such as spatial learning and memory, accompany insensitivity to leptin [19,20].

3. Leptin Regulation of Hippocampal Excitatory Synaptic Function

3.1. SC-CA1 Synapses

Immunocytochemical studies performed on cultured hippocampal neurons provided the first experimental evidence for expression of LepRs at hippocampal synapses [21], as LepR-positive immunolabelling was not only detected on principal CA1 neurons but also co-localised with the synaptic marker, synapsin-1. Subsequent electrophysiological studies observed that application of leptin depressed excitatory synaptic transmission at Schaffer-collateral (SC)-CA1 synapses in acute hippocampal slices obtained from juvenile (P11-18) rats [22]; an effect that was readily reversed on washout of leptin. The ability of leptin to reversibly depress hippocampal excitatory synaptic transmission at SC-CA1 synapses has been observed in mouse and rats at similar developmental stages [23,24]. In P5-8 hippocampal slices, leptin induces a novel form of *N*-Methyl-D-aspartate (NMDA) receptor-dependent long-term depression (LTD) [25]. In contrast, in adult hippocampus (12–16 weeks), leptin has an opposing effect as it results in a long-lasting increase in excitatory synaptic transmission that persists even after washout of leptin [25]. The ability of leptin to induce long-term potentiation (LTP) at adult SC-CA1 synapses also requires NMDA receptor activation as the effects of leptin are blocked by the competitive NMDA receptor antagonist D-AP5 [24,25].

It has been hypothesised that activation of NMDA receptors comprised of different subunits underlie different forms of activity-dependent synaptic plasticity. Indeed, the use of specific pharmacological tools to block different NMDA receptor subunits revealed that LTP requires stimulation of GluN2A subunits, whereas GluN2B subunits are implicated in LTD [26,27]. Similarly, inhibition of GluN2B subunits with either ifenprodil or Ro25-6081 blocked leptin-induced LTD at P5-8 hippocampal SC-CA1 synapses, suggesting a crucial role for GluN2B subunits in this process. Activation of GluN2A subunits is

also implicated in leptin-induced LTP at adult SC-CA1 synapses as treatment of slices with the putative GluN2A antagonist, NVP-AAM077 completely blocked the ability of leptin to induce LTP [24]. In addition to the involvement of distinct NMDA receptor subunits, divergent signalling cascades are implicated in the bi-directional effects of leptin on synaptic efficacy. Thus, activation of ERK signalling is pivotal for leptin-induced LTD, whereas leptin-induced LTP in adult hippocampus requires stimulation of the PI3-kinase pathway [24].

3.2. TA-CA1 Synapses

In addition to the SC input, hippocampal CA1 neurons are directly innervated by the temporoammonic (TA) pathway, which extends from layer III of the entorhinal cortex and forms synapses within the stratum-moleculare region of CA1. TA-CA1 synapses are known to express high levels of dopamine receptors, and this feature can be used in electrophysiological studies to readily identify TA-CA1 synaptic connections. Thus, stimulation of TA-CA1 synapses can be verified by applying dopamine, which markedly depresses excitatory synaptic transmission at TA-CA1 synapses but has no effect at SC-CA1 synapses [28,29]. Recent evidence indicates that in a manner similar to SC-CA1 synapses, TA-CA1 synapses are also rapidly modulated by the hormone leptin. Thus, treatment of juvenile hippocampal slices with leptin results in the induction of a novel form of LTP at TA-CA1 synapses [29]. This contrasts with the synaptic depression induced by leptin at SC-CA1 synapses at the same stage of development. However, both these forms of leptin-driven synaptic plasticity require NMDA receptors and specifically activation of GluN2B subunits [29] synapses as leptin-induced LTP at juvenile TA-CA1 synapses is mediated by PI 3-kinase, not ERK, signalling.

In contrast to SC-CA1 synapses, at adult TA-CA1 synapses leptin has the ability to induce a novel form of LTD, a process that is NMDA receptor-dependent and specifically requires activation of GluN2A-containing NMDA receptors [30]. Moreover, activation of canonical JAK2-STAT3 signalling and subsequent endocytosis of α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors comprising GluA1 subunits is necessary for leptin-induced LTD. This novel form of LTD shows parallels to activity-dependent LTD induced at SC-CA1 synapses, as JAK-STAT signalling is also implicated in SC-CA1 LTD [31]. However, there are clear differences in the role of JAK-STAT3 in these two forms of LTD as gene transcriptional changes underlie leptin-induced LTD at TA-CA1 synapses, whereas NMDAR-dependent LTD induced at SC-CA1 synapses is independent of gene transcriptional changes.

3.3. Leptin Regulation of AMPA Receptor Trafficking

It is widely recognised that synaptic insertion and removal of specific AMPA receptor subunits play a key part in activity-dependent synaptic plasticity in the hippocampus [32]. Transient synaptic incorporation of GluA2-lacking AMPA receptors has also been reported to accompany hippocampal LTP in some studies [33,34]. In accordance with the involvement of AMPA receptor trafficking in activity-dependent LTP, the leptin-driven alteration in synaptic efficacy at adult SC-CA1 synapses involves synaptic insertion of GluA2-lacking AMPA receptors [25]. Thus, leptin-induced LTP is reversed by addition of specific inhibitors of GluA2-lacking AMPA receptors, namely, philanthotoxin. In whole-cell recordings, leptin-induced LTP is also associated with an increase in the rectification index of synaptic AMPA receptors, suggesting incorporation of GluA2-lacking AMPA receptors mediates leptin-induced LTP. In parallel studies performed in cultured hippocampal neurons and in acute brain slices, exposure to leptin culminates in an increase in the plasma membrane expression as well as the synaptic expression of the AMPA receptor subunit, GluA1 [25]. Together, these findings suggest that the ability of leptin to induce LTP at adult SC-CA1 synapses involves trafficking of GluA2-lacking AMPA receptors into hippocampal synapses.

In a similar manner, trafficking and insertion of AMPA receptors into synapses play a pivotal part in leptin-induced LTP at juvenile TA-CA1 synapses [26], as prior treatment with

philanthotoxin blocked the ability of leptin to induce LTP. The leptin-driven persistent increase in synaptic transmission was also reversed by addition of philanthotoxin, suggesting that insertion of GluA2-lacking AMPA receptors is required for leptin-induced LTP. AMPA receptor trafficking events also underlie the effects of leptin at adult TA-CA1 synapses, as removal of GluA2-lacking AMPA receptors is key for induction of LTD by leptin [30]. Together, these findings indicate that the ability of leptin to regulate the movement of AMPA receptors to and away from hippocampal synapses is key for maintaining the bi-directional effects of leptin on excitatory synaptic efficacy at TA- and SC-CA1 synapses (Figure 2).

	<u>Juvenile</u> Synaptic depression	<u>Adult</u> LTP
SC-CA1	<ul style="list-style-type: none"> • GluN2B-dependent • ERK activation • Inhibition of AMPAR EPSCs 	<ul style="list-style-type: none"> • GluN2A-dependent • PTEN inhibition • AMPAR insertion
TA-CA1	<ul style="list-style-type: none"> • GluN2B-dependent • PI3-K activation • AMPAR insertion 	<ul style="list-style-type: none"> • GluN2A-dependent • JAK2/STAT3 activation • AMPAR internalisation

Figure 2. Summary of the differential effects of leptin at Schaffer collateral (SC)-CA1 and temporoammonic (TA)-CA1 synapses. Treatment of juvenile hippocampus with leptin results in a transient synaptic depression at SC-CA1 synapses that involves GluN2B activation and stimulation of ERK. Conversely, leptin induces LTP at juvenile TA-CA1 synapses, which requires GluN2A activation and PI 3-kinase-driven synaptic insertion of GluA2-lacking AMPA receptors. At adult SC-CA1 synapses, leptin induces a novel form of LTP that is also NMDA receptor-dependent and involves synaptic insertion of GluA2-lacking AMPA receptors following inhibition of PTEN. In contrast, leptin induces long-term depression (LTD) at adult TA-CA1 synapses, and this process requires GluN2A activation and JAK2/STAT3 signalling, which results in AMPA receptor removal from synapses.

The cellular mechanisms responsible for the insertion of GluA2-lacking AMPA receptors in response to leptin has been studied in detail. Thus, using a combination of electrophysiology and immunocytochemical approaches, Moulton and colleagues (2010) observed that the leptin-driven increase in GluA1 surface expression was accompanied by an elevation of the intracellular levels of the second messenger, phosphoinositide 3,4,5-trisphosphate (PIP₃). It is well known that PIP₃ levels are regulated by the enzyme, PI 3-kinase which promotes conversion of phosphoinositide-4,5-bisphosphate (PIP₂) into PIP₃. The phosphatase and tensin homolog (PTEN) also regulates intracellular PIP₃ levels, as PTEN activity counteracts the actions of PI 3-kinase, by dephosphorylating PIP₃, which in turn promotes the generation of PIP₂. Inhibition of the phosphatase, PTEN, not only mirrored the effects of leptin but it also occluded the ability of leptin to elevate PIP₃ levels, and to traffic GluA1 to hippocampal synapses, suggesting that leptin-driven inhibition of PTEN underlies both events.

4. Leptin and the Ageing Brain

Numerous clinical studies have shown that during the human ageing process, there is a gradual decline in the functionality of metabolic systems. This has implications not only for the metabolic function of peripheral tissues, but as metabolic hormones have widespread actions in the CNS, deteriorations in metabolic function may impact not only overall brain health but also influence the risk of age-related neurodegeneration later in life. In this respect, there is good evidence supporting the notion that Alzheimer's disease (AD)

is related to dysfunctions in brain glucose metabolism which can lead to progressive and brain-region specific neuronal degeneration [35,36]. A growing body of evidence indicates that alterations in leptin function are also correlated with AD. Indeed, clinical studies have identified lifestyle factors, like diet and body weight, as having a significant impact on development of AD. In this respect, there is considerable evidence that weight gain or an obese phenotype in middle age increases AD risk [37–40]. In contrast, weight loss in elderly individuals is associated with a higher likelihood of AD [41–43], suggesting that body weight has a complex yet paradoxical effect on AD risk. It is interesting to note that the risk of developing other neurodegenerative conditions, like amyotrophic lateral sclerosis (ALS), is also influenced by body weight status [44,45].

The link between body weight and neurodegeneration risk suggest a central role for adipose tissue, and adipokines like leptin, in determining clinical outcome across a spectrum of CNS disorders including AD. In support of leptin's role in AD, the leptin system is altered in AD such that abnormally high as well as low leptin levels are reported in AD sufferers [46,47]. Moreover, in prospective studies, a lower incidence of AD was detected in individuals who had high circulating leptin levels in the absence of an obese phenotype [48]. Comparable correlations between leptin and neurodegeneration risk have been demonstrated in rodent models of AD, with APPSwe and CRND8 mouse models both displaying significantly lower circulating leptin levels than age-matched wild-type animals [49,50]. However, a complex picture is emerging of leptin's role in AD as recent clinical studies have failed to detect significant alterations in circulating leptin levels in AD patients or a direct correlation between leptin and cognitive decline [39,51,52]. A range of confounding factors, such as gender, diet, and exercise may have contributed to the reported discrepancies in these studies. As metabolic function involves close interplay between leptin and other endocrine hormones, like ghrelin and insulin, it is likely that the relative levels of these hormones, as well underlying metabolic disorders, like diabetes, all influence the overall risk of AD. Consequently, monitoring the plasma levels of leptin in isolation, may not be the best determinant of AD risk.

In addition to age-related changes in metabolic function, alterations in neuronal responsiveness to metabolic hormones with age have been observed. Indeed, numerous studies have identified significant reductions in the insulin system, including downregulation of receptors and associated signalling cascades, as a result of the ageing process [53,54]. In accordance with this, deterioration in leptin responsiveness and leptin receptor functionality are also associated with the ageing process. For instance, studies in hypothalamic neurons demonstrated that the ability of leptin to regulate satiety is markedly reduced in aged compared to adult rats [55] and altered hypothalamic leptin-responsiveness is linked to diminished capacity to stimulate STAT3 signalling [56]. Significant changes in leptin function are also observed in the hippocampus with age. Thus, studies comparing the age-related effects of leptin on hippocampal synaptic function detected marked variance in hippocampal responsiveness to leptin between 3–4 month and 12–14 month of age, such that the magnitude of LTP evoked by leptin at 12–14 month was ~50% less than leptin-induced LTP at 3–4 month of age [24]. As NMDA receptor activation is a pre-requisite for leptin-induced LTP, and it is known that NMDA receptor function declines with age, it is feasible that a decrease in the ability of leptin to enhance NMDA receptor function contributes to the attenuated leptin-responsiveness with age, although this remains to be determined experimentally.

4.1. Neuroprotective Actions of Leptin

Comparative studies performed in leptin-sensitive and leptin-deficient rodents were some of the first to uncover possible neuroprotective actions of leptin. Significant CNS changes including a fall in brain weight were detected in *ob/ob* mice relative to wildtype littermates, suggesting decreased neuronal viability is associated with a lack of leptin [14]. This role of leptin was further verified by the complete reversal of these brain abnormalities after treatment with leptin. Numerous studies have since confirmed a neuroprotective role

for leptin, with leptin-based treatments linked to enhanced survival of neurons as well as reduced neuronal apoptosis in response to various toxic agents [57–59]. Recent evidence indicates that leptin-driven improvements in mitochondrial function may contribute to leptin-driven increases in neuronal viability [60]. Accumulating evidence indicates that leptin displays neurotrophic properties, but this may be restricted to specific neuronal populations and brain regions. For example, leptin is reported to selectively promote neurite outgrowth from cerebellar purkinje, but not granule, cells [61].

The neuroprotective effects of leptin extend to various models of CNS-driven disease including models of ischaemia [62–64]. Indeed, after transient periods of ischaemia, treatment with leptin is reported to reduce the size of cerebral infarcts and degree of brain oedema [65]. Leptin treatment also promotes an increase in the levels of ATP and p-Akt, at the same time as reducing the levels of lactate dehydrogenase, which will ultimately lead to overall enhanced neuronal cell survival in ischaemic stroke models.

Protective actions of leptin have been observed in several neurodegenerative models that replicate key pathological features of Parkinson’s disease [57,66,67] and AD [50,68,69]. In AD, build-up of toxic β -amyloid ($A\beta$) is known to promote formation of amyloid plaques, and that accumulation of $A\beta$ involves proteolytic processing of amyloid precursor protein (APP), with specific generation of the toxic forms of $A\beta$ driven by sequential β - and γ -secretase cleavage of APP. Expression of β - and γ -secretase is downregulated by leptin, which would lead to reduced levels of toxic $A\beta$, due to enhanced APP cleavage by α -secretase [70–72]. Studies in neuronal cells have demonstrated that leptin directly interferes with $A\beta$ levels via blocking β -secretase action [72]. Leptin also diminishes the extracellular levels of $A\beta$ by driving $A\beta$ uptake into cells [73] (Figure 3). Furthermore, treatment of an AD rodent model with leptin gives rise to a significant reduction in brain amyloid load [68]. Introduction of leptin into APP/PS1 mice using lentiviral gene therapy approaches results in an overall decrease in $A\beta$ accumulation as well as recovery of some of the AD-related synaptic deficits [74,75]. Together, these studies indicate that leptin not only interferes with APP-dependent generation of $A\beta$ but it also limits its toxic accumulation in neurons.




Figure 3. Leptin prevents the aberrant toxic effects of β -amyloid ($A\beta$) at synapses. Cleavage of amyloid precursor protein (APP) by the sequential actions of Beta secretase-1 (BACE1) and γ -secretase generates $A\beta$ protein that readily aggregates into oligomeric forms of $A\beta$. Acute exposure to $A\beta$ oligomers promotes toxic actions at synapses that include tau phosphorylation, AMPA receptor endocytosis, and block of hippocampal LTP. Chronic exposure to $A\beta$ leads to plaque formation and enhanced cell death. Leptin prevents the acute effects of $A\beta$ on synaptic function, and it limits $A\beta$ production and overall brain load, by reducing BACE1 activity, and promoting degradation of $A\beta$.

Another key pathological feature of AD is the formation of neurofibrillary tangles, composed of hyper-phosphorylated tau. One of the key enzymes that regulate the phosphorylation status of tau is glycogen synthase kinase 3 β (GSK3 β), a serine/threonine protein kinase, which is inhibited by PI 3-kinase. Recent studies indicate that leptin inhibits activation of GSK3 β , via stimulation of PI 3-kinase, and that activation of this LepR-signalling pathway limits tau phosphorylation [73,76]. Exposure to leptin is also reported to decrease the levels of phosphorylated tau (p-tau) in rodent models of AD [73]. The ability of leptin to regulate the levels of p-tau is supported by histological studies as raised levels of p-tau are observed in cortical tissue from Zucker *fa/fa* rats compared to Zucker lean rats, suggesting that leptin-insensitivity boosts tau phosphorylation [77]. Transgenic mice that display resistance to leptin also exhibit elevated levels of p-tau compared to wild-type controls [78]. These findings provide further verification that lack or insensitivity to leptin enhances phosphorylation of tau.

4.2. Leptin Prevents A β -Driven Impairments at Hippocampal Synapses

It is well established that acute exposure to oligomeric A β ₁₋₄₂ has damaging effects at excitatory synapses. Indeed, one consequence of treating brain slices with A β ₁₋₄₂ is that there is inhibition of LTP at hippocampal SC-CA1 synapses [79]. Additionally, activity-dependent induction of LTD is facilitated in slices exposed to A β ₁₋₄₂ and this process is thought to involve the A β ₁₋₄₂-driven removal of synaptic AMPA receptors [80]. Recent electrophysiological studies indicate that prior treatment of acute hippocampal slices with leptin prevents these aberrant effects of A β such that the ability of A β ₁₋₄₂ to inhibit LTP and to facilitate LTD is blocked by leptin [77]. Moreover, exposure of cultured hippocampal neurons to leptin prevents A β ₁₋₄₂-driven removal of GluA1-containing AMPA receptors from hippocampal synapses [77]. PI 3-kinase is implicated in the protective actions of leptin at synapses as the beneficial effect of leptin in preventing A β ₁₋₄₂ inhibition of LTP is blocked by pharmacological inhibition of PI 3-kinase. The capacity of leptin to limit A β ₁₋₄₂-driven AMPA receptor endocytosis is also hindered by PI 3-kinase inhibitors [77]. As exposure to A β ₁₋₄₂ promotes cleavage of Akt, which in turn limits inhibition of GSK-3 β [81], it is feasible that leptin counteracts this chain of events via activation of PI 3-kinase and subsequent inhibition of GSK-3 β . In support of this possibility, administration of pharmacological inhibitors of GSK-3 β not only replicate but also occlude the effects of leptin [73].

4.3. Leptin Improves Hippocampus-Dependent Learning and Memory

It is widely accepted that activity-dependent synaptic plasticity is likely to be a key cellular process involved in hippocampal-dependent learning and memory [82]. As significant evidence now suggests that leptin facilitates the same cellular events that underpin hippocampal learning and memory, it is likely that leptin also influences hippocampus-dependent behaviours. Indeed, several studies have observed improved performance in various hippocampus-dependent learning and memory tasks in rodents treated with leptin. Thus, the ability of rodents to perform spatial memory tasks in the Morris water maze improves after intravenous administration of leptin [83], whereas insensitivity to leptin is associated with impaired performance in hippocampus-specific memory tasks [19,20]. Dietary changes that lead to leptin resistance in rodents are also associated with significant impairments in novel object recognition tasks [84]. Conversely, peripheral administration of leptin enhances the ability of mice to recognize novel objects [85].

Numerous studies support the notion that the detrimental effects of A β ₁₋₄₂ on hippocampal synaptic function result in cognitive impairments, and these events closely correlate with the memory deficits and impaired cognitive function that occur in human cases of AD. In accordance with leptin's ability to prevent the aberrant actions of A β ₁₋₄₂ at hippocampal synapses, treatment with leptin also improves cognitive function in rodent models of AD. Thus, direct administration of leptin into the hippocampal formation boosts memory retention in SAMP8 mice, as evidenced by improved performance in T-maze and

passive avoidance behavioural paradigms [49]. Performance in novel object recognition assays is also improved in CRND8 transgenic mice in response to leptin treatment [73]. Furthermore, deficits in spatial memory due to intracerebroventricular application of toxic $A\beta_{1-42}$ are attenuated in rats following treatment with leptin [69]. In addition, lentiviral administration of leptin directly into brain ventricles counteracts the reported impairments in hippocampal-dependent memory in APP/PS1 transgenic mice [75]. Consequently, there is now good evidence from studies in wild-type animals and in various disease models that leptin augments cognitive function and specifically enhances hippocampus-driven memory processes.

5. Targeting the Leptin System as a Novel Therapeutic in AD?

Leptin is known to be safe for human use and it is already licensed as an anti-obesity treatment. Clinical studies where leptin has been used to treat obesity have identified that leptin also exhibits beneficial cognitive properties, which parallel the cognitive-enhancing actions of leptin in rodents. Thus, in functional brain imaging studies of individuals with congenital leptin deficiencies, Matochik and colleagues [86] found that leptin treatment enhanced gray matter volume, which is indicative of improved cognitive function. Moreover, cognitive deficits in a 5-year-old child, who was unable to produce leptin due to a leptin (*ob*) gene mutation, also markedly improved in response to a leptin treatment strategy [87]. These studies reiterate that leptin-based therapies are safe for use in humans, but also that leptin can readily penetrate the CNS and target key brain regions, like the hippocampus, that are key for higher cognitive functions. Although there is now good experimental evidence supporting the beneficial effects of leptin in AD models, studies in human AD patients have yet to be performed and thus the potential therapeutic efficacy of leptin in AD remains to be examined in a clinical setting. However, given what is already known about the central actions of leptin, it is feasible that not all AD patients would respond to leptin-based therapies. Consequently, identifying patients who would likely benefit would be crucial in clinical trials. Thus, individuals with midlife obesity and leptin resistance may not respond, whereas treatment with leptin may offer significant benefit to patients with low circulating leptin levels.

One area that offers new hope for an AD therapy is in the possible use of leptin-based peptide molecules that mimic the actions of leptin. In this respect, fragments of the whole leptin molecule have already been identified as having anti-obesity actions in various studies [88,89]. Recent studies have extended these findings to show that one specific leptin fragment, namely, leptin₁₁₆₋₁₃₀, not only displays hippocampal bioactivity but it replicates the cognitive-enhancing actions of leptin by facilitating the induction of hippocampal LTP, and by driving insertion of GluA1-containing AMPA receptors into synapses [85]. In addition, mice perform much better in episodic-like memory tasks after peripheral administration of leptin₁₁₆₋₁₃₀, compared to mice treated with vehicle. Moreover, leptin's neuroprotective actions are mirrored by leptin₁₁₆₋₁₃₀, as treatment with this leptin fragment prevents the detrimental effects of $A\beta_{1-42}$ as the ability of $A\beta_{1-42}$ to prevent hippocampal LTP induction and to promote internalization of GluA1 subunits are blocked by leptin₁₁₆₋₁₃₀ [85]. Although these findings are promising, further pre-clinical studies in rodent models of AD are required, before verifying that leptin₁₁₆₋₁₃₀, or related peptides are suitable clinical targets.

6. Protective Actions of Leptin in Other Neurodegenerative Diseases

In accordance with the proposed link between metabolic imbalance, mid-life obesity and risk of AD, several other neurodegenerative conditions are also associated with altered metabolic status, including PD, Huntington's disease (HD) and multiple sclerosis (MS) [90–93]. Furthermore, the plasma levels of leptin are significantly reduced in HD and PD patients [94–96], suggesting that functioning of the leptin system is modified in these CNS disorders. Parallel changes in leptin function are also observed in rodent models of PD, with attenuated leptin levels and metabolic dysfunction key reported features of mutant

α -synuclein mice [97]. In relapsing MS patients, elevated levels of LepR expression as well as LepR signalling via STAT3 have been detected in T cells and monocytes, suggesting a possible role for leptin in MS relapse [98].

Recent studies also suggest a link between leptin and degenerative conditions affecting motor neurons, as leptin levels are elevated in ALS patients [99] and in children with spinal muscular atrophy [100]. In addition, population-based studies of German ALS patients have revealed a relationship between leptin levels and the risk of developing ALS [101]. Moreover, recent studies indicate that reducing leptin levels improves lifespan and reduces motor neuron degeneration in mutant superoxide dismutase 1 (SOD1) mice, suggesting that altering leptin levels mitigates motor neuron disease progression [102].

7. Conclusions

The neuronal actions of the metabolic hormone leptin are known to extend beyond the hypothalamus and energy homeostasis, to the hippocampal formation where leptin boosts cognitive function. In addition to regulating classical SC-CA1 synapses that play a role in spatial memory, TA-CA1 synapses have been identified as an important target for leptin. As the TA input to CA1 neurons is implicated in episodic memory, the ability of leptin to regulate this synaptic connection is likely to also influence episodic memory processes. It is widely recognized that body weight, and dysfunctions in metabolic systems, have a role to play in development of AD, and evidence from clinical studies has uncovered correlations between the plasma levels of leptin and the risk of AD. In addition, accumulating evidence indicates beneficial cognitive and neuroprotective effects of leptin and leptin fragments in a variety of different rodent models of AD. Consequently, targeting the leptin system may offer a novel therapeutic avenue for the development of an effective AD treatment. However, in the absence of clinical assessment, it is unclear how effective leptin would be. It is likely that a leptin-based therapy would not benefit individuals displaying leptin resistance, nevertheless, there are potential therapeutic benefits of leptin in AD patients with low leptin levels. Furthermore, these benefits are not restricted to AD as emerging studies suggest that other neurodegenerative diseases, like ALS, are also associated with metabolic imbalance and abnormalities in the leptin system. Further studies are needed to examine thoroughly the therapeutic potential of the leptin system in AD and other neurodegenerative disorders.

Author Contributions: Writing—original draft preparation, J.H.; writing—review and editing, J.H. and K.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Alzheimer’s Society, grant number 449 (AS-PhD-18-007).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hervey, G.R. The effects of lesions in the hypothalamus in parabiotic rats. *J. Physiol. Lond.* **1959**, *145*, 336–352. [[CrossRef](#)] [[PubMed](#)]
2. Halaas, J.L.; Gajiwala, K.S.; Maffei, M.; Cohen, S.L.; Chait, B.T.; Rabinowitz, D.; Lallone, R.L.; Burley, S.K.; Friedman, J.M. Weight-reducing effects of the plasma protein encoded by the obese gene. *Science* **1995**, *269*, 543–546. [[CrossRef](#)] [[PubMed](#)]
3. Campfield, L.A.; Smith, F.J.; Guisez, Y.; Devos, R.; Burn, P. Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. *Science* **1995**, *269*, 546–549. [[CrossRef](#)] [[PubMed](#)]
4. Banks, W.A.; Kastin, A.J.; Huang, W.; Jaspan, J.B.; Maness, L.M. Leptin enters the brain by a saturable system independent of insulin. *Peptides* **1996**, *17*, 305–311. [[CrossRef](#)]
5. Schwartz, M.W.; Seeley, R.J.; Campfield, L.A.; Burn, P.; Baskin, D.G. Identification of targets of leptin action in rat hypothalamus. *J. Clin. Investig.* **1996**, *98*, 1101–1106. [[CrossRef](#)]
6. Tartaglia, L.A.; Dembski, M.; Weng, X.; Deng, N.; Culpepper, J.; Devos, R.; Richards, G.J.; Campfield, L.A.; Clark, F.T.; Deeds, J.; et al. Identification and expression cloning of a leptin receptor, OB-R. *Cell* **1995**, *83*, 1263–1271. [[CrossRef](#)]
7. Ihle, J.N. Cytokine receptor signalling. *Nature* **1995**, *377*, 591–594. [[CrossRef](#)]
8. Kile, B.T.; Alexander, W.S. The suppressors of cytokine signalling (SOCS). *Cell. Mol. Life Sci.* **2001**, *58*, 1627–1635. [[CrossRef](#)]
9. McGregor, G.; Harvey, J. Leptin regulation of synaptic function at hippocampal TA-CA1 and SC-CA1 synapses: Implications for health and disease. *Neurochem. Res.* **2019**, *44*, 650–660. [[CrossRef](#)]

10. Elmquist, J.K.; Bjorbaek, C.; Ahima, R.S.; Flier, J.S.; Saper, C.B. Distributions of leptin receptor mRNA isoforms in the rat brain. *J. Comp. Neurol.* **1998**, *395*, 535–547. [[CrossRef](#)]
11. Burguera, B.; Couce, M.E.; Long, J.; Lamsam, J.; Laakso, K.; Jensen, M.D.; Parisi, J.E.; Lloyd, R.V. The long form of the leptin receptor (OB-Rb) is widely expressed in the human brain. *Neuroendocrinology* **2000**, *71*, 187–195. [[CrossRef](#)] [[PubMed](#)]
12. Mercer, J.G.; Hoggard, N.; Williams, L.M.; Lawrence, C.B.; Hannah, L.T.; Trayhurn, P. Localization of leptin receptor mRNA and the long form splice variant (Ob-Rb) in mouse hypothalamus and adjacent brain regions by in situ hybridization. *FEBS Lett.* **1996**, *387*, 113–116. [[CrossRef](#)]
13. Håkansson, M.L.; Brown, H.; Ghilardi, N.; Skoda, R.C.; Meister, B. Leptin receptor immunoreactivity in chemically defined target neurons of the hypothalamus. *J. Neurosci.* **1998**, *18*, 559–572. [[CrossRef](#)] [[PubMed](#)]
14. Ahima, R.S.; Bjorbaek, C.; Osei, S.; Flier, J.S. Regulation of neuronal and glial proteins by leptin: Implications for brain development. *Endocrinology* **1999**, *140*, 2755–2762. [[CrossRef](#)] [[PubMed](#)]
15. Ahima, R.S.; Prabakaran, D.; Flier, J.S. Postnatal leptin surge and regulation of circadian rhythm of leptin by feeding. Implications for energy homeostasis and neuroendocrine function. *J. Clin. Investig.* **1998**, *101*, 1020–1027. [[CrossRef](#)] [[PubMed](#)]
16. Bouret, S.G.; Draper, S.J.; Simerly, R.B. Trophic action of leptin on hypothalamic neurons that regulate feeding. *Science* **2004**, *304*, 108–110. [[CrossRef](#)]
17. Harvey, J.; Shanley, L.; O'Malley, D.; Irving, A. Leptin: A potential cognitive enhancer? *Biochem. Soc. Trans.* **2005**, *33*, 1029. [[CrossRef](#)]
18. Irving, A.J.; Harvey, J. Leptin regulation of hippocampal synaptic function in health and disease. *Philos. Trans. R Soc. Lond. B Biol. Sci.* **2014**, *369*, 20130155. [[CrossRef](#)]
19. Li, X.L.; Aou, S.; Oomura, Y.; Hori, N.; Fukunaga, K.; Hori, T. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. *Neuroscience* **2002**, *113*, 607–615. [[CrossRef](#)]
20. Winocur, G.; Greenwood, C.E.; Piroli, G.G.; Grillo, C.A.; Reznikov, L.R.; Reagan, L.P.; McEwen, B.S. Memory impairment in obese Zucker rats: An investigation of cognitive function in an animal model of insulin resistance and obesity. *Behav. Neurosci.* **2005**, *119*, 1389–1395. [[CrossRef](#)] [[PubMed](#)]
21. Shanley, L.; O'Malley, D.; Irving, A.; Ashford, M.; Harvey, J. Leptin inhibits epileptiform-like activity in rat hippocampal neurones via PI 3-kinase-driven activation of BK channels. *J. Physiol.* **2002**, *545*, 933–944. [[CrossRef](#)] [[PubMed](#)]
22. Shanley, L.J.; Irving, A.J.; Harvey, J. Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. *J. Neurosci.* **2001**, *21*, RC186. [[CrossRef](#)] [[PubMed](#)]
23. Xu, L.; Rensing, N.; Yang, X.F.; Zhang, H.X.; Thio, L.L.; Rothman, S.M.; Weisenfeld, A.E.; Wong, M.; Yamada, K.A. Leptin inhibits 4-aminopyridine- and pentylenetetrazole-induced seizures and AMPAR-mediated synaptic transmission in rodents. *J. Clin. Investig.* **2008**, *118*, 272–280. [[CrossRef](#)] [[PubMed](#)]
24. Moulton, P.R.; Harvey, J. NMDA receptor subunit composition determines the polarity of leptin-induced synaptic plasticity. *Neuropharmacology* **2011**, *61*, 924–936. [[CrossRef](#)] [[PubMed](#)]
25. Moulton, P.R.; Cross, A.; Santos, S.D.; Carvalho, A.L.; Lindsay, Y.; Connolly, C.N.; Irving, A.J.; Leslie, N.R.; Harvey, J. Leptin regulates AMPA receptor trafficking via PTEN inhibition. *J. Neurosci.* **2010**, *30*, 4088–4101. [[CrossRef](#)]
26. Liu, L.; Wong, T.P.; Pozza, M.F.; Lingenhoehl, K.; Wang, Y.; Sheng, M.; Auberson, Y.P.; Wang, Y.T. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. *Science* **2004**, *304*, 1021–1024. [[CrossRef](#)]
27. Bartlett, T.E.; Bannister, N.J.; Collett, V.J.; Dargan, S.L.; Massey, P.V.; Bortolotto, Z.A.; Fitzjohn, S.M.; Bashir, Z.I.; Collingridge, G.L.; Lodge, D. Differential roles of NR2A and NR2B-containing NMDA receptors in LTP and LTD in the CA1 region of two-week old rat hippocampus. *Neuropharmacology* **2007**, *52*, 60–70. [[CrossRef](#)]
28. Otmakhova, N.; Lisman, J.E. Dopamine selectively inhibits the direct cortical pathway to the CA1 hippocampal region. *J. Neurosci.* **1999**, *19*, 1437–1445. [[CrossRef](#)]
29. Luo, X.; McGregor, G.; Irving, A.J.; Harvey, J. Leptin induces a novel form of NMDA receptor-dependent LTP at hippocampal temporoammonic-CA1 synapses. *eNeuro* **2015**, *2*, 1–17. [[CrossRef](#)]
30. McGregor, G.; Clements, L.; Farah, A.; Irving, A.J.; Harvey, J. Age-dependent regulation of excitatory synaptic transmission at hippocampal temporoammonic-CA1 synapses by leptin. *Neurobiol. Aging* **2018**, *69*, 76–93. [[CrossRef](#)]
31. Nicolas, C.; Peineau, S.; Amici, M.; Csaba, Z.; Fafouri, A.; Javalet, C.; Collett, V.J.; Hildebrandt, L.; Seaton, G.; Choi, S.L.; et al. The JAK/STAT pathway is involved in synaptic plasticity. *Neuron* **2012**, *73*, 374–390. [[CrossRef](#)]
32. Collingridge, G.L.; Isaac, J.T.; Wang, Y.T. Receptor trafficking and synaptic plasticity. *Nat. Rev. Neurosci.* **2004**, *5*, 952–962. [[CrossRef](#)] [[PubMed](#)]
33. Plant, K.; Pelkey, K.A.; Bortolotto, Z.A.; Morita, D.; Terashima, A.; McBain, C.J.; Collingridge, G.L.; Isaac, J.T. Transient incorporation of native GluR2-lacking AMPA receptors during hippocampal long-term potentiation. *Nat. Neurosci.* **2006**, *9*, 602–604. [[CrossRef](#)] [[PubMed](#)]
34. Morita, D.; Rah, J.C.; Isaac, J.T. Incorporation of inwardly rectifying AMPA receptors at silent synapses during hippocampal long-term potentiation. *Philos. Trans. R Soc. Lond. B Biol. Sci.* **2014**, *369*, 20130156. [[CrossRef](#)] [[PubMed](#)]
35. Stranahan, A.M.; Mattson, M.P. Bidirectional metabolic regulation of neurocognitive function. *Neurobiol. Learn. Mem.* **2011**, *96*, 507–516. [[CrossRef](#)] [[PubMed](#)]

36. Cunnane, S.C.; Trushina, E.; Morland, C.; Prigione, A.; Casadesus, G.; Andrews, Z.B.; Beal, M.F.; Bergersen, L.H.; Brinton, R.D.; de la Monte, S.; et al. Brain energy rescue: An emerging therapeutic concept for neurodegenerative disorders of ageing. *Nat. Rev. Drug Discov.* **2020**, *19*, 609–633. [[CrossRef](#)]
37. Hassing, L.B.; Dahl, A.K.; Thorvaldsson, V.; Berg, S.; Gatz, M.; Pedersen, N.L.; Johansson, B. Overweight in midlife and risk of dementia: A 40-year follow-up study. *Int. J. Obes.* **2009**, *33*, 893–898. [[CrossRef](#)]
38. Xu, W.L.; Atti, A.R.; Gatz, M.; Pedersen, N.L.; Johansson, B.; Fratiglioni, L. Midlife overweight and obesity increase late-life dementia risk: A population-based twin study. *Neurology* **2011**, *76*, 1568–1574. [[CrossRef](#)]
39. Gustafson, D.R.; Bäckman, K.; Joas, E.; Waern, M.; Östling, S.; Guo, X.; Skoog, I. 37 years of body mass index and dementia: Observations from the prospective population study of women in Gothenburg, Sweden. *J. Alzheimers Dis.* **2012**, *28*, 163–171. [[CrossRef](#)]
40. Alhurani, R.E.; Vassilaki, M.; Aakre, J.A.; Mielke, M.M.; Kremers, W.K.; Machulda, M.M.; Geda, Y.E.; Knopman, D.S.; Petersen, R.C.; Roberts, R.O. Decline in Weight and Incident Mild Cognitive Impairment: Mayo Clinic Study of Aging. *JAMA Neurol.* **2016**, *73*, 439–446. [[CrossRef](#)]
41. Power, D.A.; Noel, J.; Collins, R.; O'Neill, D. Circulating leptin levels and weight loss in Alzheimer's disease patients. *Dement. Geriatr. Cogn. Disord.* **2001**, *12*, 167–170. [[CrossRef](#)]
42. Gao, S.; Nguyen, J.T.; Hendrie, H.C.; Unverzagt, F.W.; Hake, A.; Smith-Gamble, V.; Hall, K. Accelerated weight loss and incident dementia in an elderly African-American cohort. *J. Am. Geriatr. Soc.* **2011**, *59*, 18–25. [[CrossRef](#)] [[PubMed](#)]
43. Joo, S.H.; Yun, S.H.; Kang, D.W.; Hahn, C.T.; Lim, H.K.; Lee, C.U. Body Mass Index in Mild Cognitive Impairment According to Age, Sex, Cognitive Intervention, and Hypertension and Risk of Progression to Alzheimer's Disease. *Front. Psychiatry* **2018**, *9*, 142. [[CrossRef](#)] [[PubMed](#)]
44. Paganoni, S.; Deng, J.; Jaffa, M.; Cudkowicz, M.E.; Wills, A.M. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. *Muscle Nerve* **2011**, *44*, 20–24. [[CrossRef](#)] [[PubMed](#)]
45. Gallo, V.; Wark, P.A.; Jenab, M.; Pearce, N.; Brayne, C.; Vermeulen, R.; Andersen, P.M.; Hallmans, G.; Kyrozi, A.; Vanacore, N.; et al. Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: The EPIC cohort. *Neurology* **2013**, *80*, 829–838. [[CrossRef](#)] [[PubMed](#)]
46. Bonda, D.J.; Stone, J.G.; Torres, S.L.; Siedlak, S.L.; Perry, G.; Kryscio, R.; Jicha, G.; Casadesus, G.; Smith, M.A.; Zhu, X.; et al. Dysregulation of leptin signaling in Alzheimer disease: Evidence for neuronal leptin resistance. *J. Neurochem.* **2014**, *128*, 162–172. [[CrossRef](#)]
47. Bigalke, B.; Schreitmüller, B.; Sopova, K.; Paul, A.; Stransky, E.; Gawaz, M.; Stellos, K.; Laske, C. Adipocytokines and CD34 progenitor cells in Alzheimer's disease. *PLoS ONE* **2011**, *6*, e20286. [[CrossRef](#)]
48. Lieb, W.; Beiser, A.S.; Vasan, R.S.; Tan, Z.S.; Au, R.; Harris, T.B.; Roubenoff, R.; Auerbach, S.; DeCarli, C.; Wolf, P.A.; et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. *JAMA* **2009**, *302*, 2565–2572. [[CrossRef](#)]
49. Farr, S.A.; Banks, W.A.; Morley, J.E. Effects of leptin on memory processing. *Peptides* **2006**, *27*, 1420–1425. [[CrossRef](#)]
50. Greco, S.J.; Bryan, K.J.; Sarkar, S.; Zhu, X.; Smith, M.A.; Ashford, J.W.; Johnston, J.M.; Tezapsidis, N.; Casadesus, G.J. Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. *J. Alzheimers Dis.* **2010**, *19*, 1155–1167. [[CrossRef](#)]
51. Teunissen, C.E.; van de Flier, W.M.; Scheltens, P.; Duits, A.; Wijnstok, N.; Nijpels, G.; Dekker, J.M.; Blankenstein, R.M.; Heijboer, A.C. Serum leptin is not altered nor related to cognitive decline in Alzheimer's disease. *J. Alzheimers Dis.* **2015**, *44*, 809–813. [[CrossRef](#)] [[PubMed](#)]
52. Oania, R.; McEvoy, L.K. Plasma leptin levels are not predictive of dementia in patients with mild cognitive impairment. *Age Ageing* **2015**, *44*, 53–58. [[CrossRef](#)] [[PubMed](#)]
53. De Felice, F.G.; Ferreira, S.T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. *Diabetes* **2014**, 632262–632272. [[CrossRef](#)] [[PubMed](#)]
54. Zaia, A.; Piantanelli, L. Insulin receptors in the brain cortex of aging mice. *Mech. Ageing Dev.* **2000**, *113*, 227–232. [[CrossRef](#)]
55. Shek, E.W.; Scarpance, P.J. Resistance to the anorexigenic and thermogenic effects of centrally administered leptin in obese aged rats. *Regul. Pept.* **2000**, *92*, 65–71. [[CrossRef](#)]
56. Scarpance, P.J.; Matheny, M.; Tümer, N. Hypothalamic leptin resistance is associated with impaired leptin signal transduction in aged obese rats. *Neuroscience* **2001**, *104*, 1111–1117. [[CrossRef](#)]
57. Doherty, G.H.; Oldreive, C.; Harvey, J. Neuroprotective actions of leptin on central and peripheral neurons in vitro. *Neuroscience* **2008**, *154*, 1297–1307. [[CrossRef](#)]
58. Davis, C.; Mudd, J.; Hawkins, M. Neuroprotective effects of leptin in the context of obesity and metabolic disorders. *Neurobiol. Dis.* **2014**, *72*, 61–71. [[CrossRef](#)]
59. Guo, Z.; Jiang, H.; Xu, X.; Duan, W.; Mattson, M.P. Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK/STAT3 and mitochondrial stabilization. *J. Biol. Chem.* **2008**, *283*, 1754–1763. [[CrossRef](#)]
60. Cheng, Y.; Buchan, M.; Vitanova, K.; Aitken, L.; Gunn-Moore, F.J.; Ramsay, R.R.; Doherty, G. Neuroprotective actions of leptin facilitated through balancing mitochondrial morphology and improving mitochondrial function. *J. Neurochem.* **2020**, *155*, 191–206. [[CrossRef](#)]

61. Oldreive, C.E.; Harvey, J.; Doherty, G.H. Neurotrophic effects of leptin on cerebellar Purkinje but not granule neurons in vitro. *Neurosci. Lett.* **2008**, *438*, 17–21. [[CrossRef](#)] [[PubMed](#)]
62. Zhang, F.; Chen, J. Leptin protects hippocampal CA1 neurons against ischemic injury. *J. Neurochem.* **2008**, *107*, 578–587. [[CrossRef](#)] [[PubMed](#)]
63. Zhang, W.F.; Jin, Y.C.; Li, X.M.; Yang, Z.; Wang, D.; Cui, J.J. Protective effects of leptin against cerebral ischemia/reperfusion injury. *Exp. Ther. Med.* **2019**, *17*, 3282–3290. [[CrossRef](#)] [[PubMed](#)]
64. Amantea, D.; Tassorelli, C.; Russo, R.; Petrelli, F.; Morrone, L.A.; Bagetta, G.; Corasaniti, M.T. Neuroprotection by leptin in a rat model of permanent cerebral ischemia: Effects on STAT3 phosphorylation in discrete cells of the brain. *Cell Death Dis.* **2011**, *2*, e238. [[CrossRef](#)]
65. Busch, H.J.; Schirmer, S.H.; Jost, M.; van Stijn, S.; Peters, S.L.M.; Piek, J.J.; Bode, C.; Buschmann, I.R.; Mies, G. Leptin augments cerebral hemodynamic reserve after three-vessel occlusion: Distinct effects on cerebrovascular tone and proliferation in a nonlethal model of hypoperfused rat brain. *J. Cereb. Blood Flow. Metab.* **2011**, *31*, 1085–1092. [[CrossRef](#)]
66. Weng, Z.; Signore, A.P.; Gao, Y.; Wang, S.; Zhang, F.; Hastings, T.; Yin, X.M.; Chen, J. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling. *J. Biol. Chem.* **2008**, *282*, 34479–34491. [[CrossRef](#)]
67. Lu, J.; Park, C.S.; Lee, S.K.; Shin, D.W.; Kang, J.H. Leptin inhibits 1-methyl-4-phenylpyridinium-induced cell death in SH-SY5Y cells. *Neurosci. Lett.* **2006**, *407*, 240–243. [[CrossRef](#)]
68. Fewlass, D.C.; Noboa, K.; Pi-Sunyer, F.X.; Johnston, J.M.; Yan, S.D.; Tezapsidis, N. Obesity-related leptin regulates Alzheimer's Abeta. *FASEB J.* **2004**, *18*, 1870–1878. [[CrossRef](#)]
69. Tong, J.Q.; Zhang, J.; Hao, M.; Yang, J.; Han, Y.F.; Liu, X.J.; Shi, H.; Wu, M.N.; Liu, Q.S.; Qi, J.S. Leptin attenuates the detrimental effects of β -amyloid on spatial memory and hippocampal later-phase long term potentiation in rats. *Horm. Behav.* **2015**, *73*, 125–130. [[CrossRef](#)]
70. Marwarha, G.; Dasari, B.; Prasanthi, J.R.; Schommer, J.; Ghribi, O. Leptin reduces the accumulation of A β and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. *J. Alzheimers Dis.* **2010**, *19*, 1007–1019. [[CrossRef](#)]
71. Marwarha, G.; Raza, S.; Meiers, C.; Ghribi, O. Leptin attenuates BACE1 expression and amyloid- β genesis via the activation of SIRT1 signaling pathway. *Biochim. Biophys. Acta Mol. Basis Dis.* **2014**, *1842*, 1587–1595. [[CrossRef](#)] [[PubMed](#)]
72. Niedowicz, D.M.; Studzinski, C.M.; Weidner, A.M.; Platt, T.L.; Kingry, K.N.; Beckett, T.L.; Bruce-Keller, A.J.; Keller, J.N.; Murphy, M.P. Leptin regulates amyloid β production via the γ -secretase complex. *Biochim. Biophys. Acta* **2013**, *1832*, 439–444. [[CrossRef](#)] [[PubMed](#)]
73. Greco, S.J.; Sarkar, S.; Casadesus, G.; Zhu, X.; Smith, M.A.; Ashford, J.W.; Johnston, J.M.; Tezapsidis, N. Leptin inhibits glycogen synthase kinase-3 β to prevent tau phosphorylation in neuronal cells. *Neurosci. Lett.* **2019**, *455*, 191–194. [[CrossRef](#)] [[PubMed](#)]
74. Pérez-González, R.; Antequera, D.; Vargas, T.; Spuch, C.; Bolós, M.; Carro, E. Leptin induces proliferation of neuronal progenitors and neuroprotection in a mouse model of Alzheimer's disease. *J. Alzheimers Dis.* **2011**, *24* (Suppl. 2), 17–25. [[CrossRef](#)]
75. Perez-Gonzalez, R.O.; Alvira-Botero, M.X.; Robayo, O.; Antequera, D.; Garzon, M.; Martín-Moreno, A.M.; Brera, B.; de Ceballos, M.L.; Carro, E. Leptin gene therapy attenuates neuronal damages evoked by amyloid- β and rescues memory deficits in APP/PS1 mice. *Gene Ther.* **2014**, *21*, 298–308. [[CrossRef](#)] [[PubMed](#)]
76. Zhang, Z.; Guo, M.; Zhang, J.; Du, C.; Xing, Y. Leptin Regulates Tau Phosphorylation through Wnt Signaling Pathway in PC12 Cells. *Neurosignals* **2016**, *24*, 95–101. [[CrossRef](#)] [[PubMed](#)]
77. Doherty, G.H.; Beccano-Kelly, D.; Yan, S.D.; Gunn-Moore, F.J.; Harvey, J. Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid β . *Neurobiol. Aging* **2013**, *34*, 226–237. [[CrossRef](#)] [[PubMed](#)]
78. Platt, T.L.; Beckett, T.L.; Kohler, K.; Niedowicz, D.M.; Murphy, M.P. Obesity, diabetes and leptin resistance promote tau pathology in a mouse model of disease. *Neuroscience* **2016**, *315*, 162–174. [[CrossRef](#)] [[PubMed](#)]
79. Shankar, G.M.; Li, S.; Mehta, T.H.; Garcia-Munoz, A.; Shepardson, N.E.; Smith, I.; Brett, F.M.; Farrell, M.A.; Rowan, M.J.; Lemere, C.A.; et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat. Med.* **2008**, *14*, 837–842. [[CrossRef](#)] [[PubMed](#)]
80. Li, S.; Hong, S.; Shepardson, N.E.; Walsh, D.M.; Shankar, G.M.; Selkoe, D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. *Neuron* **2009**, *62*, 788–801. [[CrossRef](#)]
81. Jo, J.; Whitcomb, D.J.; Olsen, K.M.; Kerrigan, T.L.; Lo, S.C.; Bru-Mercier, G.; Dickinson, B.; Scullion, S.; Sheng, M.; Collingridge, G.; et al. A β (1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3 β . *Nat. Neurosci.* **2011**, *14*, 545–547. [[CrossRef](#)] [[PubMed](#)]
82. Bliss, T.V.; Collingridge, G.L. A synaptic model of memory: Long-term potentiation in the hippocampus. *Nature* **1993**, *361*, 31–39. [[CrossRef](#)] [[PubMed](#)]
83. Oomura, Y.; Hori, N.; Shiraishi, T.; Fukunaga, K.; Takeda, H.; Tsuji, M.; Matsumiya, T.; Ishibashi, M.; Aou, S.; Li, X.L.; et al. Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. *Peptides* **2006**, *27*, 2738–2749. [[CrossRef](#)] [[PubMed](#)]
84. Zanini, P.; Arbo, B.D.; Niches, G.; Czarnabay, D.; Benetti, F.; Ribeiro, M.F.; Ceconello, A.L. Diet-induced obesity alters memory consolidation in female rats. *Physiol. Behav.* **2017**, *180*, 91–97. [[CrossRef](#)] [[PubMed](#)]
85. Malekizadeh, Y.; Holiday, A.; Redfeard, D.; Ainge, J.A.; Doherty, G.; Harvey, J. A leptin fragment mirrors the cognitive enhancing and neuroprotective actions of leptin. *Cereb. Cortex.* **2017**, *27*, 4769–4782. [[CrossRef](#)]

86. Matochik, J.A.; London, E.D.; Yildiz, B.O.; Ozata, M.; Caglayan, S.; DePaoli, A.M.; Wong, M.L.; Licinio, J. Effect of leptin replacement on brain structure in genetically leptin-deficient adults. *J. Clin. Endocrinol. Metab.* **2005**, *90*, 2851–2854. [[CrossRef](#)]
87. Paz-Filho, G.J.; Babikian, T.; Asarnow, R.; Esposito, K.; Erol, H.K.; Wong, M.L.; Licinio, J. Leptin replacement improves cognitive development. *PLoS ONE* **2008**, *8*, e3098. [[CrossRef](#)]
88. Grasso, P.; Leinung, M.C.; Ingher, S.P.; Lee, D.W. In vivo effects of leptin-related synthetic peptides on body weight and food intake in female ob/ob mice: Localization of leptin activity to domains between amino acid residues 106–140. *Endocrinology* **1997**, *138*, 1413–1418. [[CrossRef](#)]
89. Rozhavskaia-Arena, M.; Lee, D.W.; Leinung, M.C.; Grasso, P. Design of a synthetic leptin agonist: Effects on energy balance, glucose homeostasis and thermoregulation. *Endocrinology* **2000**, *141*, 2501–2507. [[CrossRef](#)]
90. Abbott, R.D.; Ross, G.W.; White, L.R.; Nelson, J.S.; Masaki, K.H.; Tanner, C.M.; Curb, J.D.; Blanchette, P.L.; Popper, J.S.; Petrovitch, H. Midlife adiposity and the future risk of Parkinson’s disease. *Neurology* **2002**, *59*, 1051–1057. [[CrossRef](#)]
91. Procaccini, C.; Santopaolo, M.; Faicchia, D.; Colamatteo, A.; Formisano, L.; de Candia, P.; Galgani, M.; de Rosa, V.; Matarese, G. Role of metabolism in neurodegenerative disorders. *Metab. Clin. Exp.* **2016**, *65*, 1376–1390. [[CrossRef](#)] [[PubMed](#)]
92. Gaba, A.M.; Zhang, K.; Marder, K.; Moskowitz, C.B.; Werner, P.; Boozer, C.N. Energy balance in early-stage Huntington disease. *Am. J. Clin. Nutr.* **2005**, *81*, 1335–1341. [[CrossRef](#)] [[PubMed](#)]
93. Munger, K.L.; Chitnis, T.; Ascherio, A. Body size and risk of MS in two cohorts of US women. *Neurology* **2009**, *73*, 1543–1550. [[CrossRef](#)] [[PubMed](#)]
94. Pratley, R.E.; Salbe, A.D.; Ravussin, E.; Caviness, J.N. Higher sedentary energy expenditure in patients with Huntington’s. *Ann. Neurol.* **2000**, *47*, 64–70. [[CrossRef](#)]
95. Popovic, V.; Svetel, M.; Djurovic, M.; Petrovic, S.; Doknic, M.; Pekic, S.; Miljic, D.; Milic, N.; Glodic, J.; Dieguez, C.; et al. Circulating and cerebrospinal fluid ghrelin and leptin: Potential role in altered body weight in Huntington’s disease. *Eur. J. Endocrinol.* **2004**, *151*, 451–455. [[CrossRef](#)] [[PubMed](#)]
96. Evidente, V.G.; Caviness, J.N.; Adler, C.H.; Gwinn-Hardy, K.A.; Pratley, R.E. Serum leptin concentrations and satiety in Parkinson’s disease patients with and without weight loss. *Mov. Disord.* **2001**, *16*, 924–927. [[CrossRef](#)]
97. Rothman, S.M.; Griffioen, K.J.; Fishbein, K.W.; Spencer, R.G.; Makrogiannis, S.; Cong, W.N.; Martin, B.; Mattson, M.P. Metabolic abnormalities and hypoleptinemia in α -synuclein A53T mutant mice. *Neurobiol. Aging* **2014**, *35*, 1153–1161. [[CrossRef](#)]
98. Frisullo, G.; Mirabella, M.; Angelucci, F.; Caggiula, M.; Morosetti, R.; Sancricca, C.; Patanella, A.K.; Nociti, V.; Iorio, R.; Bianco, A.; et al. The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signaling-3 expression in relapsing-remitting multiple sclerosis. *J. Neuroimmunol.* **2007**, *192*, 174–183. [[CrossRef](#)]
99. Ahmed, R.M.; Phan, K.; Highton-Williamson, E.; Strikwerda-Brown, C.; Caga, J.; Ramsey, E.; Zoing, M.; Devenney, E.; Kim, W.S.; Hodges, J.R.; et al. Eating peptides: Biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. *Ann. Clin. Transl. Neurol.* **2019**, *6*, 486–495. [[CrossRef](#)]
100. Kölbel, H.; Hauffa, B.P.; Wudy, S.A.; Bouikidis, A.; Della Marina, A.; Schara, U. Hyperleptinemia in children with autosomal recessive spinal muscular atrophy type I-III. *PLoS ONE* **2017**, *12*, e0173144. [[CrossRef](#)]
101. Nagel, G.; Peter, R.S.; Rosenbohm, A.; Koenig, W.; Dupuis, L.; Rothenbacher, D.; Ludolph, A.C. Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis—Results from a population-based ALS registry in Germany. *Sci. Rep.* **2017**, *7*, 4374. [[CrossRef](#)] [[PubMed](#)]
102. Lim, M.A.; Bence, K.K.; Sandesara, I.; Andreux, P.; Auwerx, J.; Ishibashi, J.; Seale, P.; Kalb, R.G. Genetically altering organismal metabolism by leptin-deficiency benefits a mouse model of amyotrophic lateral sclerosis. *Hum. Mol. Genet.* **2014**, *23*, 4995–5008. [[CrossRef](#)] [[PubMed](#)]